1. Home
  2. ACHV vs UYSC Comparison

ACHV vs UYSC Comparison

Compare ACHV & UYSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACHV
  • UYSC
  • Stock Information
  • Founded
  • ACHV N/A
  • UYSC 2024
  • Country
  • ACHV United States
  • UYSC United States
  • Employees
  • ACHV N/A
  • UYSC N/A
  • Industry
  • ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • UYSC Blank Checks
  • Sector
  • ACHV Health Care
  • UYSC Finance
  • Exchange
  • ACHV Nasdaq
  • UYSC Nasdaq
  • Market Cap
  • ACHV 72.5M
  • UYSC 76.5M
  • IPO Year
  • ACHV N/A
  • UYSC 2025
  • Fundamental
  • Price
  • ACHV $2.23
  • UYSC $10.04
  • Analyst Decision
  • ACHV Strong Buy
  • UYSC
  • Analyst Count
  • ACHV 3
  • UYSC 0
  • Target Price
  • ACHV $14.33
  • UYSC N/A
  • AVG Volume (30 Days)
  • ACHV 1.2M
  • UYSC 8.0K
  • Earning Date
  • ACHV 08-12-2025
  • UYSC 01-01-0001
  • Dividend Yield
  • ACHV N/A
  • UYSC N/A
  • EPS Growth
  • ACHV N/A
  • UYSC N/A
  • EPS
  • ACHV N/A
  • UYSC N/A
  • Revenue
  • ACHV N/A
  • UYSC N/A
  • Revenue This Year
  • ACHV N/A
  • UYSC N/A
  • Revenue Next Year
  • ACHV N/A
  • UYSC N/A
  • P/E Ratio
  • ACHV N/A
  • UYSC N/A
  • Revenue Growth
  • ACHV N/A
  • UYSC N/A
  • 52 Week Low
  • ACHV $1.84
  • UYSC $10.05
  • 52 Week High
  • ACHV $5.31
  • UYSC $11.00
  • Technical
  • Relative Strength Index (RSI)
  • ACHV 33.69
  • UYSC N/A
  • Support Level
  • ACHV $2.00
  • UYSC N/A
  • Resistance Level
  • ACHV $3.90
  • UYSC N/A
  • Average True Range (ATR)
  • ACHV 0.29
  • UYSC 0.00
  • MACD
  • ACHV -0.18
  • UYSC 0.00
  • Stochastic Oscillator
  • ACHV 8.91
  • UYSC 0.00

About ACHV Achieve Life Sciences Inc.

Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.

About UYSC UY Scuti Acquisition Corp. Ordinary Shares

UY Scuti Acquisition Corp is a newly organized blank check company.

Share on Social Networks: